Bafna Pharmaceuticals Limited has issued a clarification to stock exchanges regarding significant movement in its share price, responding to queries received from both BSE and NSE on April 13, 2026.

Response to Exchange Queries

The Chennai-based pharmaceutical company addressed the concerns raised by the exchanges through formal communications. The company received queries from NSE (Reference No. NSE/CM/Surveillance/16817) and BSE (Reference No. L/SURV/ONL/PV/APJ/2026-2027/3719), both dated April 13, 2026, seeking clarification on the notable price movement in the company's shares.

Company's Position on Price Movement

In its response, Bafna Pharmaceuticals clarified that it is neither aware of nor has withheld any information or events that could have influenced the significant movement in its share price. The company emphasized that the price movement appears to be market-driven and can be attributed to general market conditions and prevailing investor sentiments.

The management specifically stated that neither the company nor its leadership has any connection with or control over the share price movements on stock exchange platforms. This clarification aims to address any speculation about undisclosed corporate developments that might have triggered the price volatility.

Regulatory Compliance Commitment

Bafna Pharmaceuticals reaffirmed its commitment to maintaining transparency and regulatory compliance. The company stated that it has complied and will continue to comply with all applicable disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

The clarification was signed by Mohanachandran A, Company Secretary & Compliance Officer, and submitted to both exchanges on April 15, 2026. The company requested the exchanges to take the clarification on record, demonstrating its proactive approach to addressing regulatory queries and maintaining market transparency.

Bafna Pharmaceuticals Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 to stock exchanges, confirming adherence to dematerialisation requirements for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the certificate under Regulation 74(5) of SEBI Depositories Regulations with both BSE Limited and National Stock Exchange of India Limited on April 13, 2026. Company Secretary and Compliance Officer Mohanachandran A signed the submission digitally, ensuring proper documentation of the regulatory requirement.

Registrar Confirmation

Cameo Corporate Services Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on April 6, 2026. The registrar confirmed that securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to depositories within stipulated timeframes.

Dematerialisation Process Compliance

The certificate confirms that all security certificates received for dematerialisation were properly mutilated and cancelled after due verification by depository participants. The registrar verified that depositories' names were substituted in the register of members as registered owners within the stipulated time limits under the captioned regulations.

Key compliance confirmations include:

• Securities received from depository participants were confirmed to depositories
• Security certificates were mutilated and cancelled after proper verification
• Depository names were substituted in member registers within required timeframes
• All securities remain listed on stock exchanges where earlier issued securities are traded

Corporate Information

Bafna Pharmaceuticals Limited operates from its registered office at Bafna Towers, No.299, Thambu Chetty Street, Chennai. The company maintains its corporate identification number as L24294TN1995PLC030698 and continues its regulatory compliance obligations as a publicly listed pharmaceutical company.